Head to head
Trontinemab against Remternetug
The two next generation anti-amyloid antibodies, one using a transferrin receptor shuttle to cross into the brain and one designed for at-home subcutaneous injection. Both are in phase 3 and neither has been compared with the other.
Column A
TrontinemabTrontinemab (RG6102), Brainshuttle anti-amyloid antibody
Roche's anti-amyloid antibody with a transferrin-receptor 'shuttle' that cleared amyloid in 91% of patients within seven months at a fraction of the ARIA seen with lecanemab or donanemab; Phase 3 started in 2025.
Column B
RemternetugRemternetug (LY3372993)
Lilly's next-generation, self-injected successor to donanemab designed for at-home injection, with a Phase 3 that completed in 2026 and results pending.
Side by side, on the facts we can check
| Attribute | Trontinemab | Remternetug |
|---|---|---|
| Category | Nootropic & CNS | Nootropic & CNS |
| FDA status | Investigational; Phase 3 | Investigational; Phase 3 |
| Half-life | Not established (antibody; monthly then quarterly intravenous dosing) | Subcutaneous dosing; interval per protocol |
| Molecular weight | 194,407 Da (Brainshuttle antibody fusion) | 144,883 Da (monoclonal antibody) |
| Mechanism | Anti-amyloid-beta antibody engineered for receptor-mediated transport across the blood-brain barrier, enabling rapid plaque removal at low systemic doses. | Monoclonal antibody against N3pG amyloid-beta that promotes plaque clearance through microglial phagocytosis. |
| Human studies cited | 3 | 2 |
| Legal status, US | Investigational, not approved | Investigational, not approved |
Frequently asked questions
What is the difference between Trontinemab and Remternetug?
Trontinemab: Roche's anti-amyloid antibody with a transferrin-receptor 'shuttle' that cleared amyloid in 91% of patients within seven months at a fraction of the ARIA seen with lecanemab or donanemab; Phase 3 started in 2025. Remternetug: Lilly's next-generation, self-injected successor to donanemab designed for at-home injection, with a Phase 3 that completed in 2026 and results pending.
Which has stronger research evidence, Trontinemab or Remternetug?
This database does not grade compounds. It counts what was run in people: 3 of the 3 studies cited on the Trontinemab profile were human work, against 2 of 2 for Remternetug. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Trontinemab and Remternetug FDA-approved?
Trontinemab: Investigational; Phase 3. Remternetug: Investigational; Phase 3.
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.